GlaxoSmithKline scores new win for 2-drug HIV regimen, this time in long-acting version

15th August 2018 Uncategorised 0

Pushing ahead with its ambition for two-drug HIV therapies to challenge archrival Gilead Sciences, GlaxoSmithKline’s ViiV Healthcare is touting new data on a monthly, two-drug injection co-developed with Johnson & Johnson.

More: GlaxoSmithKline scores new win for 2-drug HIV regimen, this time in long-acting version
Source: fierce